STOCK TITAN

Simulations Plus Inc Stock Price, News & Analysis

SLP Nasdaq

Welcome to our dedicated page for Simulations Plus news (Ticker: SLP), a resource for investors and traders seeking the latest updates and insights on Simulations Plus stock.

Simulations Plus Inc (NASDAQ: SLP) is a leading provider of modeling software and consulting services for pharmaceutical research and regulatory compliance. This page serves as the definitive source for official company announcements and market-moving developments.

Access real-time updates on earnings reports, strategic partnerships, product innovations, and regulatory milestones. Our curated news collection helps stakeholders track advancements in ADMET prediction tools, PBPK modeling capabilities, and drug development consulting services.

Discover press releases covering software updates, research collaborations, and industry recognitions. Stay informed about initiatives impacting pharmaceutical R&D efficiency and global regulatory submissions. Content is verified through primary sources to ensure accuracy and relevance.

Bookmark this page for streamlined access to Simulations Plus' latest business developments. Combine these updates with our comprehensive company profile for informed analysis of SLP's market position in computational pharmacology solutions.

Rhea-AI Summary

Simulations Plus (Nasdaq: SLP), a leading biosimulation and medical communications solutions provider, announces its participation in the upcoming BTIG Digital Health Forum on November 25, 2024. CEO Shawn O'Connor will join a panel discussion on 'Supporting Drug Development, Clinical Trials, and Biopharma' at 2:00 p.m. Eastern Time and conduct one-on-one meetings throughout the day. Interested participants must pre-register through the BTIG website to attend the virtual event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.37%
Tags
conferences
-
Rhea-AI Summary

Simulations Plus (Nasdaq: SLP) and the University of Connecticut have received a new FDA grant to expand mechanistic modeling for long-acting injectable (LAI) technologies. The collaboration will use GastroPlus® PBPK platform to investigate relationships between LAI formulation and physiological factors at injection sites. The project aims to develop models that could serve as alternatives to in vivo studies for establishing bioequivalence. Dr. Diane Burgess's lab will generate vital data for marketed LAI suspension products, while Simulations Plus will develop PBPK models for validation. The initiative seeks to reduce development time and costs while streamlining regulatory processes for both innovator and generic formulations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.31%
Tags
-
Rhea-AI Summary

Simulations Plus (Nasdaq: SLP), a leading biosimulation and medical communications solutions provider for the biopharma industry, announced its participation in the Stephens Annual Investment Conference in Nashville. CEO Shawn O'Connor will engage in a fireside chat on November 20, 2024, at 12:00 p.m. Eastern Time and conduct one-on-one investor meetings throughout the day. The presentation will be available via live audio webcast, with a 90-day replay accessible on the company's Investors page.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.76%
Tags
conferences
Rhea-AI Summary

Simulations Plus (Nasdaq: SLP) has secured a new FDA grant in partnership with the University of Strathclyde and InnoGI Technologies. The collaboration aims to improve understanding of amorphous solid dispersion (ASD) formulations and predict food and pH-dependent drug-drug interactions through in vitro testing and simulation. The project will utilize GastroPlus® platform for physiologically based pharmacokinetic modeling to link in vitro dissolution with in vivo data. The research is expected to accelerate formulation adjustments, reduce costs, and speed up time-to-market for both innovator and generic ASD products.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.6%
Tags
-
Rhea-AI Summary

Simulations Plus (Nasdaq: SLP) reported strong fiscal 2024 results with total revenue growing 18% to $70.0 million. Software revenue increased 12% to $41.0 million (59% of total), while services revenue rose 26% to $29.0 million (41% of total). The company reported net income of $10.0 million with diluted EPS of $0.49. The acquisition of Pro-ficiency in June doubled their total addressable market to $8 billion. For fiscal 2025, the company provides revenue guidance of $90-93 million (+28-33%) and adjusted diluted EPS guidance of $1.07-1.20.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.89%
Tags
-
Rhea-AI Summary

Simulations Plus (Nasdaq: SLP) has announced its upcoming fourth quarter and fiscal 2024 financial results release, scheduled for Wednesday, October 23, 2024, after the market close. The company will host a conference call and live webcast on the same day at 5:00 p.m. Eastern Time to discuss the results.

Interested parties, including investment professionals and shareholders, can join the webcast by registering online. Alternatively, participants can dial in using 1-877-451-6152 (domestic) or 1-201-389-0879 (international) numbers. A 'Call me' link is also available for those requesting a return call.

The webcast will be accessible on the Simulations Plus investor relations page, where it will remain available for replay approximately one hour after the call concludes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.3%
Tags
conferences earnings
Rhea-AI Summary

Simulations Plus and the University of Southern California have secured an NIH grant to develop new AI drug discovery offerings. The partnership aims to advance ligand-based virtual screening by incorporating water-ligand interactions into drug design and optimization activities.

The project will integrate USC's WATGEN algorithm for predicting water positions with Simulations Plus's ADMET Predictor platform. Machine learning approaches will be applied to predict pharmacophore features for 3D shape and feature matching. The goal is to create a first-of-its-kind LBVS solution that enhances current methods and accelerates the discovery of more effective drugs.

The team will validate the technology by designing drugs against defined targets, synthesizing and testing selected compounds experimentally. This collaboration between industry and academia aims to reduce the Design-Make-Test-Analyze cycle of drug discovery significantly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.24%
Tags
AI
-
Rhea-AI Summary

Simulations Plus (Nasdaq: SLP), a leading provider of biosimulation and medical communications solutions for the biopharma industry, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. The event will take place on September 6, 2024, at the Marriott Marquis in New York.

CEO Shawn O'Connor will represent the company, hosting one-on-one and small group meetings throughout the day. This prestigious conference is expected to feature over 200 companies and attract a prominent group of investors, including chief investment officers, portfolio managers, and analysts.

The conference provides an excellent opportunity for Simulations Plus to showcase its innovative solutions and network with key industry players and investors. For those interested in learning more about the event, additional information can be found on the Morgan Stanley conference website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.42%
Tags
conferences
-
Rhea-AI Summary

Simulations Plus (Nasdaq: SLP) has announced a strategic restructuring of its business units and leadership to support future growth following recent acquisitions. The company is forming two new business units: Adaptive Learning & Insights and Medical Communications, while transitioning Regulatory Strategies into a Center of Excellence. This reorganization aims to enhance customer engagement, accelerate cross-selling opportunities, and maximize growth potential.

Key leadership changes include:

  • Steven Chang promoted to President, Quantitative Systems Pharmacology
  • Jenna Rouse promoted to President of Adaptive Learning & Insights
  • Murry Alper promoted to President of Medical Communications
  • Sandra Suarez-Sharp transitioning to President, Regulatory Strategies Center of Excellence
The restructuring is set to take effect on August 30, 2024, positioning Simulations Plus to leverage its expanded capabilities across the drug development continuum.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.96%
Tags
News
Rhea-AI Summary

Simulations Plus (Nasdaq: SLP) has released DILIsym® version X (DSX), an updated quantitative systems toxicology (QST) platform. DSX is designed to predict drug-induced liver injury (DILI) risks, supporting critical drug development decisions. The software features:

- Enhanced processing speed
- Improved user interface
- Command line and graphical interface options
- Licensing for scale-up on local or cloud clusters
- Four new exemplar compounds
- Two new simulated populations

DSX aims to help researchers identify potential DILI risks, design mitigating dosing strategies, and make faster go/no-go decisions. This can lead to more efficient drug development processes, potentially reducing costly failed clinical trials and accelerating safe drug delivery to patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.08%
Tags
none

FAQ

What is the current stock price of Simulations Plus (SLP)?

The current stock price of Simulations Plus (SLP) is $33.56 as of May 1, 2025.

What is the market cap of Simulations Plus (SLP)?

The market cap of Simulations Plus (SLP) is approximately 709.1M.
Simulations Plus Inc

Nasdaq:SLP

SLP Rankings

SLP Stock Data

709.12M
16.57M
17.74%
80.28%
8.69%
Health Information Services
Services-computer Integrated Systems Design
Link
United States
RESEARCH TRIANGLE PARK